Ovarian Cancer
Left Ovary Carcinoma
Female, 71 years
Patient Internal ID: 183649376
ICD-10 code
C56 Malignant Neoplasm of Ovary
Diagnosis (Incl. Metastases/Stage) and Year
March 2011
Adenocarcinoma of Left Ovary, pT1cN0M0 Stage I. Disease progression in November 2018, Metastasis in Pelvic Area. Disease progression in April 2021, pT1cN2M1 G3 Stage 4, PR+, ER+ Metastasis in Spleen, Pelvic Lymph Nodes. Disease progression in July 2022, Metastasis in the Lungs, Pelvis area.
Previous Treatment
Surgery, Chemotherapy (Carboplatin), Surgery, Chemotherapy (Paclitaxel and Carboplatin) + Biological therapy (Bevacizumab), Chemotherapy (Carboplatin and Gemcitabine), Chemotherapy (Carboplatin).
Prognosis and Survival Expectation
The Metastatic Ovarian Cancer prognosis remains poor, with a median survival of ~32 months from diagnosis. The average relative 5-year survival rate for Distant Spread Ovarian Cancer is about 31%.
Treatment Provided
Autologous DCV (9 doses) over a period of 11 months.
Patient Survival/Condition and Year
Date of Review: 17/02/2024
The patient has survived for 11,5 years since diagnosis and 49 months since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Surgery, has extended patient survival by an estimate of around 17 months.
